关键数据
1.820今开
1.950最高
667.00成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.01%换手率
1.810昨收
1.750最低
1.17K成交额
亏损市盈率静
0.54市净率
0.00%股息率 TTM
-28.93%ROA
3.06552周最高
0.07量比
-13.56M净利润
10.87M总股本
-4.6080每股收益TTM
0.24Beta
-97.42%ROE
1.75052周最低
9.39%振幅
59.62%毛利率
19.89M总市值
3.12回报/风险
2.79%风险率

即将为您带来更多新闻,敬请期待。。。
Aytu Biopharma Inc评分
0.06与上次评分对比预测8.00
财务诊断7.23
技术分析3.97
公司估值8.74
机构认同度3.00
风险评估4.02
分析师评级
买入评级
9.667目标均价
+400.86%涨幅空间
Aytu Biopharma Inc 最新财报电话会记录
Aytu BioPharma (AYTU) 2026财年第四季度业绩电话会:EXXUA增长与2027财年展望
随着EXXUA销售额达到390万美元,Aytu BioPharma 2026财年第四季度营收增长6%至1610万美元。管理层阐述了2027财年的支出及利润率目标。
财务指标
货币: USD

由于公司未披露,未能获取相关数据
货币: USD

由于公司未披露,未能获取相关数据
Aytu Biopharma Inc 简介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
行业药品
公司代码AYTU
员工数量82
国家United States of America
持股情况
| 持股股东 | 占比 |
|---|
| Nantahala Capital Management, LLC | 10.13% |
|---|
| Stonepine Capital Management, LLC | 7.58% |
|---|
| AWM Investment Company, Inc. | 5.77% |
|---|
| Lytton (Laurence W) | 4.99% |
|---|
| 股东类型 | 占比 |
|---|
| Investment Advisor/Hedge Fund | 16.18% |
|---|
| Hedge Fund | 16.10% |
|---|
| Individual Investor | 8.98% |
|---|
| Investment Advisor | 3.85% |
|---|
常见问题
Aytu Biopharma Inc(AYTU)的当前股价是多少?
Aytu Biopharma Inc(AYTU)的当前股价是 1.83。
Aytu Biopharma Inc的股票代码是什么?
Aytu Biopharma Inc的股票代码是AYTU。
Aytu Biopharma Inc股票的52周最高点是多少?
Aytu Biopharma Inc股票的52周最高点是3.06。
Aytu Biopharma Inc股票的52周最低点是多少?
Aytu Biopharma Inc股票的52周最低点是1.75。
Aytu Biopharma Inc的市值是多少?
Aytu Biopharma Inc的市值是19.89M。
现在Aytu Biopharma Inc(AYTU)的股票是买入、持有还是卖出?
根据分析师评级,Aytu Biopharma Inc(AYTU)的总体评级为买入,目标价格为9.67。
Aytu Biopharma Inc(AYTU)股票的每股收益(EPS TTM)是多少
Aytu Biopharma Inc(AYTU)股票的每股收益(EPS TTM)是-4.61。